Surgical Resection Is Better than Transarterial Chemoembolization for Hepatocellular Carcinoma Beyond Milan Criteria Independent of Performance Status

Journal of Gastrointestinal Surgery

Volumn 18, Issue 9, 2014, Pages 1623-1631

  Liu, Po Hong ^a,b   Lee, Yun Hsuan ^a,b   Hsu, Chia Yang ^a,b,c   Hsia, Cheng Yuan ^a,b   Huang, Yi Hsiang ^a,b   Chiou, Yi You ^a,b   Lin, Han Chieh ^a,b   Huo, Teh Ia ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hepatocellular carcinoma; Milan criteria; Performance status; Surgical resection; Transarterial chemoembolization

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; ETHIODIZED OIL;

AGED; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION; FEMALE; HUMAN; LIVER NEOPLASMS; LIVER RESECTION; MALE; MIDDLE AGED; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DOXORUBICIN; ETHIODIZED OIL; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 84929130599     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-014-2546-9     Document Type: Article

References (29)

1. Ferlay J, Shin H, Bray F, Forman D, Nathers C, Parkin D: GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iacr.fr, accessed on 01/05/2013.
2. Bruix J, Sherman M, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–1022.
3. de Lope CR, Tremosini S, Forner A, Reig M, Bruix J: Management of HCC. J Hepatol 2012;56 Suppl 1:S75–87.
4. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693–699.
5. Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Lee PC, Loong CC, Chiang JH, Huo TI, Lee SD: Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer 2010;116:3006–3014.
6. El-Serag HB, Marrero JA, Rudolph L, Reddy KR: Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008;134:1752–1763.
7. Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Pai JT, Loong CC, Chiou YY, Lee RC, Lee FY, Huo TI, Lee SD: Comparison of surgical resection and transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria: a propensity score analysis. Ann Surg Oncol 2012;19:842–849.
8. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J, Barcelona Liver Cancer G: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734–1739.
9. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–655.
10. Bruix J, Sherman M, Practice Guidelines Committee AAftSoLD: Management of hepatocellular carcinoma. Hepatology 2005;42:1208–1236.
11. Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, Lin HC, Lee RC, Chiou YY, Lee FY, Huo TI: Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. Hepatology 2013;57:112–119.
12. Grant BF, Dufour MC, Harford TC: Epidemiology of alcoholic liver disease. Seminars in Liver Disease 1988;8:12–25.
13. Hsu CY, Huang YH, Hsia CY, Su CW, Lin HC, Loong CC, Chiou YY, Chiang JH, Lee PC, Huo TI, Lee SD: A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol 2010;53:108–117.
14. Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, Neri D, Boccagni P, Srsen N, D'Amico F, Ciarleglio FA, Bridda A, D'Amico DF: Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 2006;44:723–731.
15. Huo TI, Huang YH, Lin HC, Wu JC, Chiang JH, Lee PC, Chang FY, Lee SD: Proposal of a modified Cancer of the Liver Italian Program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy. Am J Gastroenterol 2006;101:975–982.
16. Lee YH, Hsu CY, Huang YH, Su CW, Lin HC, Lee RC, Chiou YY, Huo TI, Lee SD: Selecting a prognostic renal surrogate for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Gastroenterol Hepatol 2012;27:1581–1588.
17. Pearl J. Causality: models, reasoning, and inference. Cambridge UK: Cambridge University Press, 2009.
18. D'Agostino RB, Jr.: Propensity scores in cardiovascular research. Circulation 2007;115:2340–2343.
19. Hassoun Z, Gores GJ: Treatment of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2003;1:10–18.
20. Yamashita Y, Taketomi A, Shirabe K, Aishima S, Tsuijita E, Morita K, Kayashima H, Maehara Y: Outcomes of hepatic resection for huge hepatocellular carcinoma (>/=10 cm in diameter). J Surg Oncol 2011;104:292–298.
21. Yang L, Xu J, Ou D, Wu W, Zeng Z: Hepatectomy for huge hepatocellular carcinoma: single institute's experience. World J Surg 2013;37:2189–2196.
22. Lee S, Kim BK, Kim SU, Park Y, Chang S, Park JY, do Kim Y, Ahn SH, Chon CY, Han KH: Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma. PLoS One 2013;8:e77240.
23. Jin YJ, Lee JW, Choi YJ, Chung HJ, Kim YS, Lee KY, Ahn SI, Shin WY, Cho SG, Jeon YS: Surgery versus transarterial chemoembolization for solitary large hepatocellular carcinoma of BCLC stage A. J Gastrointest Surg 2014;18:555–561.
24. Andreou A, Vauthey JN, Cherqui D, Zimmitti G, Ribero D, Truty MJ, Wei SH, Curley SA, Laurent A, Poon RT, Belghiti J, Nagorney DM, Aloia TA, International Cooperative Study Group on Hepatocellular C: Improved long-term survival after major resection for hepatocellular carcinoma: a multicenter analysis based on a new definition of major hepatectomy. J Gastrointest Surg 2013;17:66–77; discussion p 77.
25. Sumie S, Nakashima O, Okuda K, Kuromatsu R, Kawaguchi A, Nakano M, Satani M, Yamada S, Okamura S, Hori M, Kakuma T, Torimura T, Sata M: The significance of classifying microvascular invasion in patients with hepatocellular carcinoma. Ann Surg Oncol 2014;21:1002–1009.
26. Zhong JH, Ke Y, Gong WF, Xiang BD, Ma L, Ye XP, Peng T, Xie GS, Li LQ: Hepatic Resection Associated With Good Survival for Selected Patients With Intermediate and Advanced-Stage Hepatocellular Carcinoma. Ann Surg 2013.
27. Bruix J, Llovet JM: Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002;35:519–524.
28. Zhong JH, Xiang BD, Gong WF, Ke Y, Mo QG, Ma L, Liu X, Li LQ: Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization. PLoS One 2013;8:e68193.
29. Pinter M, Hucke F, Graziadei I, Vogel W, Maieron A, Konigsberg R, Stauber R, Grunberger B, Muller C, Kolblinger C, Peck-Radosavljevic M, Sieghart W: Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology 2012;263:590–599.